Left ventricular thrombus (LVT), one of the most feared and common complications of acute myocardial infarction (AMI), still causes morbidity and mortality in a proportion of patients despite the widespread use of primary percutaneous coronary intervention (PCI), which has been proven to reduce the death rate and side effects [1]. According to a recent scientific statement from the American Heart Association, vitamin K antagonists (VKAs) such as warfarin are recommended as the first-line medication for the treatment of LVT.
